Drug developers at Cell 2026

Nov 12–13, 2026 London, UK ~800 attendees Website

34 drug developers are at Cell 2026 — 77 presentations on the program. Most represented: Bristol Myers Squibb (5 on the program), AstraZeneca (4 on the program), Resolution Therapeutics (4 on the program). 23 of them have their own page in this guide. As of Oct 8, 2026.

All 109 organizations at Cell 2026 →

Showing 1–10 of 34 organizations

Organization	Cell 2026 Attendance
Bristol Myers Squibb Princeton, New Jersey
bms.com Large pharma Global drugmaker with marketed CAR-T cell therapies alongside medicines for cancer, immunology and cardiovascular disease.	Talk Thu Nov 12 9:25am–9:50am Advanced Technologies Driving The Next Wave Of Gene Therapy Cell and gene therapy Talk Thu Nov 12 10:15am–10:40am Phase Appropriate Analytical Strategies Including Comparability Analytics and characterizationManufacturing and CMC Panel Thu Nov 12 2:40pm–3:05pm Quality Control Strategies In Advanced CGTs with Quell Therapeutics, University of Liverpool Cell and gene therapyAnalytics and characterization Panel Thu Nov 12 2:40pm–3:05pm Where Does Big Pharma Stand In CGTs – And What Comes Next? with Johnson & Johnson, AstraZeneca Cell and gene therapy Talk Thu Nov 12 4:55pm–5:20pm From Vision And Concepts To Practical Execution - An Analytical Strategy And Lifecycle Execution Roadmap To Support Commercial Readiness And Operational Execution Success Analytics and characterizationManufacturing and CMC Talk Thu Nov 12 5:20pm–5:45pm One Lot, One Life: Scaling Hope for Patients with Autologous CART Treatments Cell and gene therapyManufacturing and CMC Talk Fri Nov 13 1:55pm–2:20pm Designing An End-To-End Supply Chain For CGTs Cell and gene therapyManufacturing and CMC
AstraZeneca Cambridge, UK
astrazeneca.com Large pharma Global drugmaker with medicines in oncology, cardiovascular, respiratory, immunology and rare disease, and a cell therapy pipeline.	Panel Thu Nov 12 12:25pm–12:50pm Cracking In Vivo Delivery For Next-Generation Gene Therapies with University Medical Center Freiburg, SymphoRNA, AviadoBio Cell and gene therapy Panel Thu Nov 12 12:25pm–12:50pm The Productivity Challenge: How Can The Industry Deliver More Medicines With Less with UCB Manufacturing and CMC Panel Thu Nov 12 2:40pm–3:05pm Where Does Big Pharma Stand In CGTs – And What Comes Next? with Bristol Myers Squibb, Johnson & Johnson Cell and gene therapy Talk Thu Nov 12 3:05pm–3:30pm Mapping Immune Vulnerabilities: CRISPR Screens for Target Discovery Stem cells, organoids and cell models Talk Fri Nov 13 3:10pm–3:35pm Cell Line Database Development Cell line developmentDigital biomanufacturing and AI Talk Fri Nov 13 3:50pm–4:15pm Clinical Trial Designs For Advanced Therapies Outside Of Oncology Cell and gene therapy Talk Fri Nov 13 4:15pm–4:40pm Reduction Of Animal Bi-Products In Cell Cultures Cell culture and upstream processing
Resolution Therapeutics London, UK
resolution-tx.com Biotech Develops regenerative macrophage therapies for inflammatory and fibrotic diseases, led by a programme in end-stage liver disease.	Talk Thu Nov 12 10:15am–10:40am Building For The Future: Phase-Appropriate CMC Strategies Manufacturing and CMC Panel Thu Nov 12 2:40pm–3:05pm The AI Reality Check: What’s Ready Now, What Isn’t, And How Do We Validate It Safely? with Hogan Lovells, TreeFrog Therapeutics Digital biomanufacturing and AI Panel Fri Nov 13 4:40pm–5:05pm Beyond Silos: How Cell & Gene Therapies Fit Into The Broader Biotech & Treatment Landscape with Cell and Gene Therapy Catapult, Leucid Bio Cell and gene therapy Panel Fri Nov 13 4:40pm–5:05pm Navigating The Regulatory Lifecycle Of Advanced Therapies: From Platform Approval To Manufacturing & Post-Market Evidence with Aspen Neuroscience, NHS Blood and Transplant Cell and gene therapyManufacturing and CMC Talk Fri Nov 13 5:05pm–5:30pm Developing A Regenerative Macrophage Therapy (RMT) For Fibro-Inflammatory Diseases: Challenges And Opportunities Cell and gene therapy
TreeFrog Therapeutics Bordeaux, France
treefrog.fr Biotech Develops cell therapies from pluripotent stem cells grown in its C-Stem 3D encapsulation platform, with a lead program in Parkinson's disease.	Panel Thu Nov 12 2:40pm–3:05pm The AI Reality Check: What’s Ready Now, What Isn’t, And How Do We Validate It Safely? with Hogan Lovells, Resolution Therapeutics Digital biomanufacturing and AI Panel Fri Nov 13 9:25am–9:50am Plenary Thought Leadership Panel Discussion: Turning Scientific Breakthroughs Into Sustainable Therapies – Building A Viable Business Model For CGTs with Orchard Therapeutics Cell and gene therapy Talk Fri Nov 13 11:40am–12:05pm Bridging Development and Manufacturing Through Predictive Scaling Manufacturing and CMCCell culture and upstream processing Talk Fri Nov 13 2:45pm–3:10pm Cell Therapy: From Therapeutic Potential To Sustainable Patient Access Cell and gene therapy
Autolus London, UK
autolus.com Biotech Develops and markets CAR-T cell therapies, including an approved treatment for adult acute lymphoblastic leukaemia.	Talk Thu Nov 12 3:05pm–3:30pm Harnessing Digital PCR For Rapid Sterility Testing Analytics and characterization Panel Thu Nov 12 5:20pm–5:45pm Overcoming Sterility Testing Challenges In CGT Analytical Development Analytics and characterizationCell and gene therapy Talk Fri Nov 13 5:05pm–5:30pm Developing Cutting-Edge Flow-Based Assays For Critical CMC Applications Analytics and characterizationManufacturing and CMC
AviadoBio London, UK
aviadobio.com Biotech King's College London spin-out developing gene therapies for neurodegenerative diseases such as frontotemporal dementia.	Panel Thu Nov 12 12:25pm–12:50pm Cracking In Vivo Delivery For Next-Generation Gene Therapies with University Medical Center Freiburg, SymphoRNA, AstraZeneca Cell and gene therapy Talk Thu Nov 12 2:40pm–3:05pm Manufacture Of AVB-406, A BBB-Crossing AAV Vector For MAPT Knockdown In Alzheimer's Disease Cell and gene therapyManufacturing and CMC Talk Thu Nov 12 5:45pm–6:10pm Leveraging Platform-Based RNA Silencing To Accelerate Rare Disease Therapeutic Development Cell and gene therapy
INmune Bio Boca Raton, Florida
inmunebio.com Biotech Clinical-stage company developing immune-targeted therapies, including a TNF inhibitor for neurological disease and an umbilical cord MSC therapy.	Talk Thu Nov 12 9:25am–9:50am Designing Large Scale Cell Therapies For Real-World Access Cell and gene therapyManufacturing and CMC Panel Fri Nov 13 1:55pm–2:20pm Closing The Gap: Connecting Upstream And Downstream Bioprocessing In Cell-Based Therapies with Quell Therapeutics, Technical University of Denmark Cell culture and upstream processingCell and gene therapy Talk Fri Nov 13 4:40pm–5:05pm MSC Therapies: From Decades Of Challenges To Commercial Approval Cell and gene therapyStem cells, organoids and cell models
Quell Therapeutics London, UK
quell-tx.com Biotech Develops engineered regulatory T-cell therapies for immune-mediated diseases and transplant rejection.	Panel Thu Nov 12 2:40pm–3:05pm Quality Control Strategies In Advanced CGTs with Bristol Myers Squibb, University of Liverpool Cell and gene therapyAnalytics and characterization Talk Thu Nov 12 5:20pm–5:45pm Lessons Learned From Cross-Team & Multi-Site Collaboration To Improve Assay Transfer & Scalability Analytics and characterization Panel Fri Nov 13 1:55pm–2:20pm Closing The Gap: Connecting Upstream And Downstream Bioprocessing In Cell-Based Therapies with Technical University of Denmark, INmune Bio Cell culture and upstream processingCell and gene therapy
Rinri Therapeutics Sheffield, UK
rinri-therapeutics.com Biotech Clinical-stage company developing regenerative cell therapies for sensorineural hearing loss.	Talk Thu Nov 12 4:55pm–5:20pm Featured Session: Restoring Hearing With Cell & Gene Therapies: From Bench To Bedside - Developing A World-First Regenerative Cell Therapy For Hearing Loss Cell and gene therapy Panel Thu Nov 12 5:45pm–6:10pm Featured Session: Restoring Hearing With Cell & Gene Therapies: From Bench To Bedside with University of Cambridge, Sensorion Cell and gene therapy Panel Fri Nov 13 11:40am–12:05pm From Model To Medicine: Fixing The Translation Gap with ValiRx, a:head bio, MeiraGTx Stem cells, organoids and cell models
ValiRx
valirx.com Biotech UK-listed oncology drug developer that evaluates and develops early assets; its Inaphaea BioLabs unit supplies patient-derived cancer cell models.	Panel Fri Nov 13 11:40am–12:05pm From Model To Medicine: Fixing The Translation Gap with Rinri Therapeutics, a:head bio, MeiraGTx Stem cells, organoids and cell models Talk Fri Nov 13 1:55pm–2:20pm Patient Derived Cells As New Approach Methodologies For More Predictive Oncology Models Stem cells, organoids and cell models